NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: EMCURE · data 2026-10-30
Emcure Pharmaceuticals Limited
In plain words
Price: 10.9% below its 52-week high of ₹2,100.7.
Delivery: 56.4% of traded shares were kept for delivery over the last 10 sessions, against 54.8% over the last 60.
Latest results: a net profit of ₹294 cr for the quarter ended Jun 2026 (+42.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹9,683 cr |
| Net profit (last 12 months) | ₹1,011 cr |
| Sales growth, 3 years (yearly) | 15.4% |
| Profit growth, 3 years (yearly) | 20.2% |
Latest results in brief (Q1 FY27)
EMCURE Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹2,580.45 crore, up 22.8% YoY and up 4.5% QoQ.
Net profit was ₹293.98 crore, up 42.1% YoY and up 20.8% QoQ.
Operating margin was 20.6% (19.8% a year ago).
EPS was ₹15.5, up 41.9% YoY and up 20.7% QoQ.
EMCURE के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹2,580.45 करोड़; पिछले साल की तुलना में 22.8% की बढ़त, पिछली तिमाही की तुलना में 4.5% की बढ़त।
शुद्ध मुनाफ़ा: ₹293.98 करोड़; पिछले साल की तुलना में 42.1% की बढ़त, पिछली तिमाही की तुलना में 20.8% की बढ़त।
ऑपरेटिंग मार्जिन: 20.6% (एक साल पहले 19.8%)।
EPS: ₹15.5; पिछले साल की तुलना में 41.9% की बढ़त, पिछली तिमाही की तुलना में 20.7% की बढ़त।
EMCUREના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹2,580.45 કરોડ; ગયા વર્ષની સરખામણીએ 22.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4.5% વધારો.
ચોખ્ખો નફો: ₹293.98 કરોડ; ગયા વર્ષની સરખામણીએ 42.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 20.8% વધારો.
ઓપરેટિંગ માર્જિન: 20.6% (એક વર્ષ પહેલાં 19.8%).
EPS: ₹15.5; ગયા વર્ષની સરખામણીએ 41.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 20.7% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 62.2% over the last 20 sessions vs 56.0% in the 40 before (1.11x); shares delivered per day 0.63x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 9/15: 10 schemes hold it, about ₹876 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 1/15: Verdict "None", sustained score 38/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 4 Sept 26Dividend Dividend ₹3.6 (ex-date) +3.9% next session
- 6 Aug 26Results Q1 FY27 results: profit +42.1% YoY +1.0% next session
- 5 May 26Results Q4 FY26 results: profit +28.8% YoY -7.5% next session
- 4 Feb 26Results Q3 FY26 results: profit +50.0% YoY -1.6% next session
- 11 Nov 25Results Q2 FY26 results: profit +25.1% YoY -6.3% next session
- 14 Aug 25Dividend Dividend ₹3 (ex-date) 0.0% next session
- 7 Aug 25Results Q1 FY26 results: profit +43.6% YoY -2.6% next session
- 22 May 25Results Q4 FY25 results: net profit ₹189 cr +19.6% next session
- 6 Feb 25Results Q3 FY25 results: net profit ₹153.7 cr -3.0% next session
- 8 Nov 24Results Q2 FY25 results: net profit ₹194.6 cr -0.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹2,580 cr | ₹294 cr | +42.1% | 20.6% | 15.5 |
| Mar 2026 | ₹2,470 cr | ₹243 cr | +28.8% | 19.4% | 12.84 |
| Dec 2025 | ₹2,363 cr | ₹231 cr | +50.0% | 20.8% | 12.16 |
| Sept 2025 | ₹2,270 cr | ₹243 cr | +25.1% | 20.9% | 12.85 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 77.82% | 77.83% | 77.87% | 77.87% |
| Foreign institutions (FII) | 4.94% | 4.88% | 3.35% | 3.59% |
| Domestic institutions (DII) | 8.49% | 8.46% | 6.10% | 6.10% |
| Mutual funds | 7.05% | 6.87% | 4.94% | 4.83% |
| Retail investors | 2.93% | 3.00% | 3.02% | 2.87% |
| Number of shareholders | 1,29,328 | 1,24,991 | 1,22,189 | 1,18,863 |
Common questions
What was Emcure Pharmaceuticals Limited's latest quarterly profit?
Emcure Pharmaceuticals Limited reported a net profit of ₹294 cr for the quarter ended Jun 2026 (+42.1% on the same quarter a year earlier), on revenue of ₹2,580 cr.
How much do promoters hold in Emcure Pharmaceuticals Limited?
Promoters held 77.82% of Emcure Pharmaceuticals Limited at the end of Sept 2026, with 0.04% of promoter shares pledged.
Is Emcure Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.31.
What is Emcure Pharmaceuticals Limited's P/E ratio?
About 35.1, based on the last 12 months' earnings and a price of ₹1,871.8 (data 2026-10-30).
What is the 52-week high and low of Emcure Pharmaceuticals Limited?
The 52-week high is ₹2,100.7 and the 52-week low is ₹1,306.5.
Mutual funds holding Emcure Pharmaceuticals Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 10 schemes holding about ₹876 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE ELSS TAX SAVER FUND | Aditya Birla Sun Life Mutual Fund | 1.93% | ₹262 cr |
| SBI Flexicap Fund | SBI Mutual Fund | 0.99% | ₹219 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.36% | ₹125 cr |
| ADITYA BIRLA SUN LIFE MULTI-CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.18% | ₹86 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.25% | ₹77 cr |
| ADITYA BIRLA SUN LIFE LARGE & MID CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.96% | ₹54 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 3.21% | ₹35 cr |
| An open ended fund for investment for children having a lock-in for at least 5 years or till the child attains age of majority | Aditya Birla Sun Life Mutual Fund | 1.15% | ₹14 cr |
| ADITYA BIRLA SUN LIFE RETIREMENT FUND - THE 30S PLAN | Aditya Birla Sun Life Mutual Fund | 1.37% | ₹6 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.60% | ₹0 cr |
Similar companies
Ajanta Pharma Limited (AJANTPHARM) · GlaxoSmithKline Pharmaceuticals Limited (GLAXO) · Acutaas Chemicals Ltd (ACUTAAS) · Wockhardt Limited (WOCKPHARMA) · Piramal Pharma Limited (PPLPHARMA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open EMCURE in NSE Scanner →